Show simple item record

dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorBeer, M.en
dc.contributor.authorTheoharis, D.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorMaravegias, A.en
dc.contributor.authorFountzilas, Georgeen
dc.creatorPavlidis, Nicholasen
dc.creatorKosmidis, Paraskevas A.en
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorBriassoulis, E. Chen
dc.creatorBeer, M.en
dc.creatorTheoharis, D.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorMaravegias, A.en
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:54:15Z
dc.date.available2018-06-22T09:54:15Z
dc.date.issued1992
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42267
dc.description.abstractSummary: In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to evaluate both the response rate and the toxicity of combination chemotherapy containing cisplatin or carboplatin, and to attempt to identify certain clinical subsets of patients sensitive to these drugs. Four patients were not evaluable and 13 (29.5%), eight of the 34 treated with regimens containing cisplatin and 5/14 with carboplatin-based chemotherapy, responded to treatment. Six of the 23 with undifferentiated tumours, 4/17 with adenocarcinomas and 3/8 with epidermoid cancers responded to chemotherapy. Four of 6 women with adenocarcinoma of the peritoneal cavity, 5/11 with undifferentiated carcinomas with midline distribution and 3/5 with epidermoid carcinomas of the cervical nodes responded. Seven patients achieved complete and six partial remissions. The mean duration of response was nine months; a number of patients enjoyed prolonged and/or durable remissions. Toxicity was tolerable. We conclude that: (a) both cisplatin and carboplatin are active agents in this syndrome with one-third of the evaluable patients responding, and (b) there may be chemosensitive subgroups, such as patients with peritoneal adenocarcinomatosis, undifferentiated carcinoma with midline distribution and metastatic epidermoid carcinoma of the neck nodes. The effectiveness of carboplatin in these patients and the responsiveness of metastatic epidermoid carcinoma of unknown origin have not been adequately dealt with in the literature. © 1992 Kluwer Academic Publishers.en
dc.language.isoengen
dc.sourceAnnals of Oncologyen
dc.subjectArticleen
dc.subjectAntineoplastic agenten
dc.subjectBleomycinen
dc.subjectCyclophosphamideen
dc.subjectEtoposideen
dc.subjectFluorouracilen
dc.subjectHumanen
dc.subjectMethotrexateen
dc.subjectNeoplasmsen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectRetrospective studiesen
dc.subjectAnemiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectCisplatinen
dc.subjectClinical articleen
dc.subjectLeukopeniaen
dc.subjectThrombocytopeniaen
dc.subjectSurvival rateen
dc.subjectCarcinomaen
dc.subjectMaleen
dc.subjectCarboplatinen
dc.subjectVomitingen
dc.subjectMitomycin cen
dc.subjectAnthracycline derivativeen
dc.subjectIfosfamideen
dc.subjectAdenocarcinomaen
dc.subjectSquamous cellen
dc.subjectSquamous cell carcinomaen
dc.subjectUnknown primaryen
dc.subjectMiddle ageen
dc.subjectCarcinoma of unknown originen
dc.subjectChemosensitive subgroupsen
dc.subjectVinca alkaloiden
dc.titleOriginal article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site: A hellenic cooperative oncology group studyen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume3
dc.description.issue8
dc.description.startingpage631
dc.description.endingpage634
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record